In 2017, a nomination was received to establish a whole genome sequencing service using Massively Parallel Sequencing (MPS). MPS is a new technology for whole exome or whole genome sequencing and has a range of applications in the prenatal, neonatal, paediatric and adult settings.
In 2017, a nomination was received to establish a new hub and spoke clinic model for the management of patients with neurofibromatosis (NF). The committee recommended that additional advice be sought from stakeholders and NSW Health bodies.
In 2018 a nomination was received for a point of care test to detect chlamydia and gonorrhoea. This is a nucleic acid amplification test approved by the Therapeutic Goods Administration. Trials of this test in rural communities showed some benefits when compared to conventional testing.